Sitagliptin Impurity 28, with the CAS number 1351498-23-1, is a chemical compound that is recognized as an impurity associated with the pharmaceutical agent sitagliptin, which is used primarily in the management of type 2 diabetes. As an impurity, it may arise during the synthesis or degradation of sitagliptin and is typically characterized by its molecular structure, which includes specific functional groups that can influence its chemical behavior and stability. The compound's characteristics, such as solubility, melting point, and reactivity, are important for understanding its potential impact on the efficacy and safety of sitagliptin formulations. Impurities like Sitagliptin Impurity 28 are subject to regulatory scrutiny, as they can affect the quality of pharmaceutical products. Analytical techniques such as HPLC (High-Performance Liquid Chromatography) and mass spectrometry are often employed to identify and quantify such impurities in drug formulations, ensuring compliance with safety standards and maintaining therapeutic effectiveness.

Sitagliptin Impurity 28

1351498-23-1: Sitagliptin Impurity 28, with the CAS number 1351498-23-1, is a chemical compound that is recognized as an impurity associated with the pharmaceutical agent sitagliptin, which is used primarily in the management of type 2 diabetes. As an impurity, it may arise during the synthesis or degradation of sitagliptin and is typically characterized by its molecular structure, which includes specific functional groups that can influence its chemical behavior and stability. The compound's characteristics, such as solubility, melting point, and reactivity, are important for understanding its potential impact on the efficacy and safety of sitagliptin formulations. Impurities like Sitagliptin Impurity 28 are subject to regulatory scrutiny, as they can affect the quality of pharmaceutical products. Analytical techniques such as HPLC (High-Performance Liquid Chromatography) and mass spectrometry are often employed to identify and quantify such impurities in drug formulations, ensuring compliance with safety standards and maintaining therapeutic effectiveness.

CAS 1351498-23-1

Sitagliptin Impurity 28

Sitagliptin Impurity 28

Ref: 4Z-S-2064

Sitagliptin Impurity 46

Ref: ST-EA-CP-S3097